002370 亚太药业
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-0.574-2.693-36.144-41.7574.220
总资产报酬率 ROA (%)-0.248-0.804-8.466-12.7991.291
投入资产回报率 ROIC (%)-0.266-0.876-9.195-14.1031.522

边际利润分析
销售毛利率 (%)31.09732.09335.77737.88150.556
营业利润率 (%)-1.044-15.085-31.216-63.2569.922
息税前利润/营业总收入 (%)4.2725.198-25.200-56.27016.953
净利润/营业总收入 (%)-1.127-2.824-35.532-72.4395.297

收益指标分析
经营活动净收益/利润总额(%)631.149551.94149.78676.828-430.596
价值变动净收益/利润总额(%)-511.700-32.98212.324-10.89317.376
营业外收支净额/利润总额(%)3.030-448.72913.85111.073-79.904

偿债能力分析
流动比率 (X)1.3185.9034.5194.6504.373
速动比率 (X)1.2175.3504.0904.3664.151
资产负债率 (%)53.94659.36280.23073.12166.242
带息债务/全部投入资本 (%)47.35152.49971.12264.228--
股东权益/带息债务 (%)103.49883.67730.46945.06865.563
股东权益/负债合计 (%)85.37168.45924.64136.76050.961
利息保障倍数 (X)0.7990.654-2.283-3.7861.482

营运能力分析
应收账款周转天数 (天)70.27572.13376.650107.1580.000
存货周转天数 (天)101.427116.376117.159115.6510.000